AVALO THERAPEUTICS, INC. Deferred Income Tax Liabilities, Net
AVALO THERAPEUTICS, INC. (AVTX) had Deferred Income Tax Liabilities, Net of $463.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Liabilities, Net $463.00K.
- 2026-03-31: Deferred Income Tax Liabilities, Net $446.00K.
- 2025-12-31: Deferred Income Tax Liabilities, Net $434.00K.
- 2025-09-30: Deferred Income Tax Liabilities, Net $304.00K.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2026-06-30 | $463.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $446.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $434.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $304.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $293.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $278.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $270.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $154.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $168.00K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $162.00K 10-Q/A · filed 2024-07-11 | |
| 2023-12-31 | $155.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $164.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $156.00K 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $148.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $141.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $133.00K 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $128.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $122.00K 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $113.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $130.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $122.00K 10-Q · filed 2021-08-02 | |
| 2021-03-31 | $111.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $90.00K 10-K · filed 2022-03-02 | $90.39K 10-K · filed 2021-03-08 |
| 2020-09-30 | $114.98K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $106.70K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $85.98K 10-K · filed 2021-03-08 | |
| 2019-09-30 | $98.06K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $88.11K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $75.18K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $69.24K 10-K · filed 2020-03-11 | |
| 2018-09-30 | $37.99K 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $30.91K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $23.06K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $7.14K 10-K · filed 2019-03-18 | |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |